Acticor Biotech SAS Management
Management criteria checks 3/4
Acticor Biotech SAS' CEO is Gilles Avenard, appointed in Oct 2021, has a tenure of 3.17 years. total yearly compensation is €361.67K, comprised of 74% salary and 26% bonuses, including company stock and options. directly owns 1.02% of the company’s shares, worth €39.91K. The average tenure of the management team and the board of directors is 3 years and 2.8 years respectively.
Key information
Gilles Avenard
Chief executive officer
€361.7k
Total compensation
| CEO salary percentage | 74.0% |
| CEO tenure | 3.2yrs |
| CEO ownership | 1.0% |
| Management average tenure | 3yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€16m |
| Mar 31 2024 | n/a | n/a | -€18m |
| Dec 31 2023 | €362k | €268k | -€19m |
| Sep 30 2023 | n/a | n/a | -€19m |
| Jun 30 2023 | n/a | n/a | -€19m |
| Mar 31 2023 | n/a | n/a | -€17m |
| Dec 31 2022 | €751k | €250k | -€16m |
| Sep 30 2022 | n/a | n/a | -€15m |
| Jun 30 2022 | n/a | n/a | -€14m |
| Mar 31 2022 | n/a | n/a | -€13m |
| Dec 31 2021 | €1m | €173k | -€13m |
Compensation vs Market: Gilles's total compensation ($USD376.42K) is about average for companies of similar size in the German market ($USD467.65K).
Compensation vs Earnings: Gilles's compensation has been consistent with company performance over the past year.
CEO
Gilles Avenard (73 yo)
3.2yrs
Tenure
€361,665
Compensation
Dr. Gilles Avenard, M.D serves as Founder at Acticor Biotech SAS and has been its Chief Executive Officer since October 14, 2021 and was its Chairman until June 2021 and serves as its Director. He serves a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 3.2yrs | €361.67k | 1.02% € 39.9k | |
| Deputy CEO | no data | €238.94k | no data | |
| Deputy CEO | 7yrs | €279.91k | no data | |
| Scientific Founder | no data | no data | no data | |
| Scientific Founder | no data | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Head of Scientific Affairs & Business Intelligence | 3.9yrs | no data | no data | |
| Head of Global Clinical Development | 2.9yrs | no data | no data | |
| Head of Clinical Operations | 1.4yrs | no data | no data |
3.0yrs
Average Tenure
71yo
Average Age
Experienced Management: 7V7's management team is considered experienced (3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | €361.67k | 1.02% € 39.9k | |
| Independent Chairman of the Board | 3.5yrs | €80.00k | 0.30% € 11.7k | |
| Director | 2.1yrs | no data | no data | |
| Director | 3.9yrs | no data | 3.14% € 123.3k | |
| Independent Director | 1.9yrs | €135.88k | no data | |
| Observer | 2.1yrs | no data | no data | |
| Independent Board Member | 6.1yrs | €30.00k | 0.0089% € 351.1 |
2.8yrs
Average Tenure
75yo
Average Age
Experienced Board: 7V7's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 19:25 |
| End of Day Share Price | 2024/10/15 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Acticor Biotech SAS is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guillaume Cuvillier | Gilbert Dupont |
| Stephanie Lefebvre | Gilbert Dupont |